MHRA Drug Safety Update
November 2023
Falsified, potentially harmful Ozempic▼ and Saxenda products have been found in the UK.
There is a risk of harmful drug interactions with the ritonavir component of the COVID-19 treatment Paxlovid▼ due to its inhibition of the enzyme CYP3A, which metabolises many commonly used drugs. Prescribers should obtain a detailed patient history of current medications before prescribing Paxlovid, checking the Paxlovid product information for known and potential drug interactions.
Healthcare professionals should be vigilant for suspected adverse reactions and safety concerns associated with e-cigarettes and e-liquids, commonly known as vapes. Please report adverse reactions to the Yellow Card scheme and promote vigilance among patients.
A summary of recent letters and notifications sent to healthcare professionals about medicines.
It's easy to report
Report a suspected adverse drug reaction online
or download the Yellow Card app
Drug Safety Update is a monthly newsletter from the Medicines and Healthcare products Regulatory Agency (MHRA) and its independent advisor the Commission on Human Medicines.
|
